ScholarIQanswers from OpenAlex

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

PaperCitations, authors & open-access status

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study have?

ScholarIQcitation count

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study has 411 citations in the OpenAlex counts ScholarIQ stores.

When was Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study published?

ScholarIQyear

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study has 2015 year in the ScholarIQ index.

What is the open-access status of Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study?

ScholarIQoa status

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study has closed oa status in the ScholarIQ index.

What is the DOI of Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study?

ScholarIQdoi

The DOI for Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study is on the source record.

What is the PMID of Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study?

ScholarIQpmid

The PMID for Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study is on the source record.

What is the OpenAlex record for Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study?

ScholarIQopenalex

The OpenAlex for Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial